Literature DB >> 30387877

Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?

Kevin Kalinsky1, Ruth M O'Regan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30387877      PMCID： PMC6329661          DOI： 10.1002/cncr.31814

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  18 in total

1.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

2.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

3.  West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Authors:  Oleg Gluz; Ulrike A Nitz; Matthias Christgen; Ronald E Kates; Steven Shak; Michael Clemens; Stefan Kraemer; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Manfred Kusche; Volker Heyl; Fatemeh Lorenz-Salehi; Marianne Just; Daniel Hofmann; Tom Degenhardt; Cornelia Liedtke; Christer Svedman; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

4.  Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.

Authors:  Ivana Sestak; Jack Cuzick; Mitch Dowsett; Elena Lopez-Knowles; Martin Filipits; Peter Dubsky; John Wayne Cowens; Sean Ferree; Carl Schaper; Christian Fesl; Michael Gnant
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

5.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors:  Fatima Cardoso; Laura J van't Veer; Jan Bogaerts; Leen Slaets; Giuseppe Viale; Suzette Delaloge; Jean-Yves Pierga; Etienne Brain; Sylvain Causeret; Mauro DeLorenzi; Annuska M Glas; Vassilis Golfinopoulos; Theodora Goulioti; Susan Knox; Erika Matos; Bart Meulemans; Peter A Neijenhuis; Ulrike Nitz; Rodolfo Passalacqua; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Christos Sotiriou; Lisette Stork; Carolyn Straehle; Geraldine Thomas; Alastair M Thompson; Jacobus M van der Hoeven; Peter Vuylsteke; René Bernards; Konstantinos Tryfonidis; Emiel Rutgers; Martine Piccart
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

6.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Authors:  Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

8.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

9.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Authors:  Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

10.  Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Ivana Sestak; Richard Buus; Jack Cuzick; Peter Dubsky; Ralf Kronenwett; Carsten Denkert; Sean Ferree; Dennis Sgroi; Catherine Schnabel; Frederick L Baehner; Elizabeth Mallon; Mitch Dowsett
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777
View more
  2 in total

1.  The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.

Authors:  Roi Weiser; Waqar Haque; Efstathia Polychronopoulou; Sandra S Hatch; Yong-Fang Kuo; William J Gradishar; V Suzanne Klimberg
Journal:  Breast Cancer Res Treat       Date:  2020-10-18       Impact factor: 4.872

2.  Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.

Authors:  Aditya K Sengupta; Aparna Gunda; Sukriti Malpani; Chandra Prakash V Serkad; Chetana Basavaraj; Ashok Bapat; Manjiri M Bakre
Journal:  Cancer Med       Date:  2020-10-07       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.